Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Mayo Clinic
Hoffmann-La Roche
ImmunoGen, Inc.
Yale University
M.D. Anderson Cancer Center
Hoffmann-La Roche
M.D. Anderson Cancer Center
GOG Foundation
Roswell Park Cancer Institute
Columbia University
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
Western Regional Medical Center
Ohio State University Comprehensive Cancer Center
Genentech, Inc.
University of Pittsburgh
Memorial Sloan Kettering Cancer Center
NYU Langone Health
Benaroya Research Institute
Ohio State University Comprehensive Cancer Center
Dana-Farber Cancer Institute
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.